TrialThorax2023

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.

Lorraine B Ware et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.